Consider Eurofins DiscoverX’s custom development capabilities for custom cell line assays, ready-to-use kits, & enzyme development.
Potency is a critical quality attribute for biologics, and regulatory expectations require assays that accurately reflect a product's mechanism of action (MOA). As products advance through development, these assays must be fully validated under GMP (Good Manufacturing Practice) compliance to seamlessly support comparability studies, stability programs, and commercial release.
Transferring an assay from development to a GMP lab is one of the biggest risks to program timelines. Re-optimization, analyst training, reagent qualification, and documentation updates all come before validation can begin. For cell-based potency assays, which depend on cell health, passage history, critical reagents, and operator expertise, these steps add delay, cost, and risk to release milestones.
Eurofins DiscoverX removes these hurdles with an in-house Assay-to-GMP™ workflow. Starting from a Eurofins DiscoverX cell line or bioassay kit, our scientists will develop, qualify, and GMP-validate a potency method using your drug candidate, then use it for routine release and stability testing. Keeping every step, including cell banking, in one organization avoids third-party transfer delays, speeds GMP readiness, and keeps your method transfer-ready if you choose to move it.
Our commercially available assays support a broad range of biologic targets and modalities, including biosimilars, multi-target biologics, and antibody-drug conjugates, across obesity, inflammation, and oncology programs. Because each program starts from an established cell line or kit rather than from scratch, your potency method moves faster into GMP release testing.

Consider Eurofins DiscoverX’s custom development capabilities for custom cell line assays, ready-to-use kits, & enzyme development.


Method characterization and validation should match the program phase, product risk, and intended use, consistent with ICH Q2(R2) and ICH Q14. Our integrated workflow below takes your drug candidate from a Eurofins DiscoverX cell line or bioassay kit to a GMP-validated potency method and routine release testing. It establishes a robust analytical foundation early, expands the evidence package as the program advances, and preserves method knowledge through transfer, validation, and routine testing.

| Stage | Key Activities | Program Output |
|---|---|---|
| 1. Assay strategy and suitability |
|
Defined development plan with fit-for-purpose performance goals |
| 2. Development and pre-qualification |
|
Documented, transfer-ready method package |
| 3. GMP method acquisition and validation |
|
GMP-validated method with controlled, filing-ready documentation suitable for its intended release and/or stability use |
| 4. Routine testing and lifecycle management |
|
Reliable long-term method performance across the product lifecycle |
| SCIENTIFIC CONTINUITY | ELIMINATE ASSAY TRANSFER DELAYS | FASTER GMP READINESS | RELEASE-READY EXECUTION |
|---|---|---|---|
| Develop from a Proven Assay Platform | One organization from development to GMP | Accelerate Validation & Release Testing | Validated Assays for Ongoing GMP Testing |
| Start with a DiscoverX cell line or bioassay kit and develop a potency method using your drug candidate. Scientific continuity helps identify cells, reagents, and method risks earlier to reduce downstream troubleshooting. | Avoid the time and risk of transferring assays between vendors. Method development, qualification, GMP validation, and testing are performed within the same organization. | Build from a well-characterized assay platform rather than starting from scratch, streamlining qualification and GMP validation while generating filing-ready documentation and release test implementation. | After GMP validation, the assay can support routine release testing, stability studies, and comparability assessments throughout the product lifecycle. |
The same program framework supports early development, clinical lot release, stability studies, process comparability, commercial readiness, and post-approval monitoring.